Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital

Publisher： Karger

E-ISSN： 1423-0399|83|4|452-457

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.83, Iss.4, 2009-12, pp. : 452-457

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

By  

Urologia Internationalis, Vol. 70, Iss. 1, 2003-02 ,pp. : 1-14

Karger

Access to resources Recommend Favorite

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 2-9

Karger

Access to resources Recommend Favorite

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

By Yasufuku Tomihiko   Shigemura Katsumi   Matsumoto Osamu   Arakawa Soichi   Fujisawa Masato  

Journal of Infection and Chemotherapy, Vol. 16, Iss. 3, 2010-06 ,pp. : 200-205

Springer Publishing Company

Access to resources Recommend Favorite

Prostate-Specific Antigen Levels and Prognosis in Patients with Hormone-Refractory Prostate Cancer Treated with Low-Dose Dexamethasone

By  

Urologia Internationalis, Vol. 68, Iss. 1, 2002-01 ,pp. : 10-15

Karger

Access to resources Recommend Favorite

Oral Combination of Cyclophosphamide, Uracil plus Tegafur and Estramustine for Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 49-54

Karger

Access to resources Recommend Favorite